Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results
April 26 2022 - 8:30AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer, today announced that it will
host a conference call on May 12, 2022 at 4:30 PM Eastern Time to
discuss results for its first quarter ended March 31, 2022.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Date: May 12, 2022Time: 4:30 PM Eastern TimeToll Free:
888-506-0062; Access Code: 824126International: 973-528-0011;
Access Code: 824126
The call will also be available over the Internet and accessible
at: https://www.webcaster4.com/Webcast/Page/2556/45171
Conference Call Replay Information
Toll Free: 877-481-4010International: 919-882-2331Replay
Passcode: 45171
Webcast replay:
https://www.webcaster4.com/Webcast/Page/2556/45171
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce
polyamine metabolic inhibition (PMI) by exploiting an observed high
affinity of the compound for pancreatic ductal adenocarcinoma and
other tumors. The molecule has shown signals of tumor growth
inhibition in clinical studies of US and Australian metastatic
pancreatic cancer patients, demonstrating a median overall survival
(OS) of 12.0 months which is not yet final, and an objective
response rate (ORR) of 48%, both exceeding what is seen typically
with the standard of care of gemcitabine + nab-paclitaxel
suggesting potential complementary activity with the existing
FDA-approved standard chemotherapy regimen. In data evaluated from
clinical studies to date, SBP-101 has not shown exacerbation of
bone marrow suppression and peripheral neuropathy, which can be
chemotherapy-related adverse events. Serious visual adverse events
have been evaluated and patients with a history of retinopathy or
at risk of retinal detachment will be excluded from future SBP-101
studies. The safety data and PMI profile observed in the current
Panbela sponsored clinical trial provides support for continued
evaluation of SBP-101 in a randomized clinical trial. For more
information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing disruptive therapeutics for patients with urgent
unmet medical needs. The company’s initial product candidate,
SBP-101, is for the treatment of patients with metastatic
pancreatic ductal adenocarcinoma, the most common type of
pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to
treating patients with pancreatic cancer, ovarian cancer, and
exploring SBP-101’s potential for efficacy in combination with
other agents in other cancer indications. Further information can
be found
at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking
statements,” including within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “believe,” “design,” “expect,” “feel,”
“intend,” “may,” “plan,” “scheduled,” and “will.”. All statements
other than statements of historical fact are statements that should
be deemed forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current
beliefs, expectations, and assumptions regarding the future of our
business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and
financial condition may differ materially and adversely from the
forward-looking statements. Therefore, you should not rely on
any of these forward-looking statements. Important factors
that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking
statements include, among others, the following: (i) our ability to
obtain additional funding to complete clinical trials; (ii)
progress and success of our Phase 1 clinical trial; (iii) the
impact of the current COVID-19 pandemic on our ability to complete
monitoring and reporting in our current clinical trial and procure
the active ingredient; (iv) our ability to demonstrate the safety
and effectiveness of our SBP-101 product candidate (v) our ability
to obtain regulatory approvals for our SBP-101 product
candidate in the United States, the European Union or other
international markets; (vi) the market acceptance and level of
future sales of our SBP-101 product candidate; (vii) the cost and
delays in product development that may result from changes in
regulatory oversight applicable to our SBP-101 product
candidate; (viii) the rate of progress in establishing
reimbursement arrangements with third-party payors; (ix) the effect
of competing technological and market developments; (x) the costs
involved in filing and prosecuting patent applications and
enforcing or defending patent claims; and (xi) such other factors
as discussed in Part I, Item 1A under the caption “Risk Factors” in
our most recent Annual Report on Form 10-K, any additional risks
presented in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Any forward-looking statement made by us in
this press release is based on information currently available to
us and speaks only as of the date on which it is made. We
undertake no obligation to publicly update any forward-looking
statement or reasons why actual results would differ from those
anticipated in any such forward-looking statement, whether
written or oral, whether as a result of new
information, future developments or otherwise.
Contact Information:
Investors: James Carbonara Hayden IR (646)
755-7412 james@haydenir.com
Media: Tammy Groene Panbela Therapeutics,
Inc. (952) 479-1196 IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Apr 2023 to Apr 2024